CA3228485A1 - Pyrazolo[3,4-b]pyridine compounds for the treatment of autoimmune disease - Google Patents
Pyrazolo[3,4-b]pyridine compounds for the treatment of autoimmune disease Download PDFInfo
- Publication number
- CA3228485A1 CA3228485A1 CA3228485A CA3228485A CA3228485A1 CA 3228485 A1 CA3228485 A1 CA 3228485A1 CA 3228485 A CA3228485 A CA 3228485A CA 3228485 A CA3228485 A CA 3228485A CA 3228485 A1 CA3228485 A1 CA 3228485A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- methy1
- methyl
- pyridy1
- piperazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021120406 | 2021-09-24 | ||
| CNPCT/CN2021/120406 | 2021-09-24 | ||
| CN2022089033 | 2022-04-25 | ||
| CNPCT/CN2022/089033 | 2022-04-25 | ||
| PCT/EP2022/076306 WO2023046806A1 (en) | 2021-09-24 | 2022-09-22 | Pyrazolo[3,4-b]pyridine compounds for the treatment of autoimmune disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3228485A1 true CA3228485A1 (en) | 2023-03-30 |
Family
ID=83688579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3228485A Pending CA3228485A1 (en) | 2021-09-24 | 2022-09-22 | Pyrazolo[3,4-b]pyridine compounds for the treatment of autoimmune disease |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240360126A1 (enExample) |
| EP (1) | EP4405051A1 (enExample) |
| JP (1) | JP2024534567A (enExample) |
| KR (1) | KR20240065092A (enExample) |
| CN (1) | CN118076604A (enExample) |
| AR (1) | AR127126A1 (enExample) |
| AU (1) | AU2022351495A1 (enExample) |
| CA (1) | CA3228485A1 (enExample) |
| CL (1) | CL2024000791A1 (enExample) |
| CO (1) | CO2024003401A2 (enExample) |
| CR (1) | CR20240134A (enExample) |
| IL (1) | IL310443A (enExample) |
| MX (1) | MX2024003444A (enExample) |
| PE (2) | PE20240815A1 (enExample) |
| TW (1) | TW202328129A (enExample) |
| WO (1) | WO2023046806A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024222889A1 (zh) * | 2023-04-28 | 2024-10-31 | 成都思倍博医药科技有限公司 | 含氧代吡啶并脂肪环或脂杂环结构的化合物及其医药用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3080124A1 (en) * | 2013-12-13 | 2016-10-19 | Takeda Pharmaceutical Company Limited | Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors |
| CR20190119A (es) | 2016-09-09 | 2019-06-03 | Novartis Ag | Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje |
| JP7407740B2 (ja) | 2018-05-18 | 2024-01-04 | ノバルティス アーゲー | Ｔｌｒ７／ｔｌｒ８阻害剤の結晶形態 |
| WO2022013136A1 (en) * | 2020-07-14 | 2022-01-20 | F. Hoffmann-La Roche Ag | Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease |
-
2022
- 2022-09-22 AU AU2022351495A patent/AU2022351495A1/en active Pending
- 2022-09-22 CN CN202280063841.XA patent/CN118076604A/zh active Pending
- 2022-09-22 CA CA3228485A patent/CA3228485A1/en active Pending
- 2022-09-22 IL IL310443A patent/IL310443A/en unknown
- 2022-09-22 MX MX2024003444A patent/MX2024003444A/es unknown
- 2022-09-22 AR ARP220102558A patent/AR127126A1/es unknown
- 2022-09-22 JP JP2024518351A patent/JP2024534567A/ja active Pending
- 2022-09-22 PE PE2024000482A patent/PE20240815A1/es unknown
- 2022-09-22 EP EP22786353.7A patent/EP4405051A1/en active Pending
- 2022-09-22 KR KR1020247009335A patent/KR20240065092A/ko active Pending
- 2022-09-22 WO PCT/EP2022/076306 patent/WO2023046806A1/en not_active Ceased
- 2022-09-22 PE PE2024003046A patent/PE20250401A1/es unknown
- 2022-09-22 CR CR20240134A patent/CR20240134A/es unknown
- 2022-09-23 TW TW111136043A patent/TW202328129A/zh unknown
-
2024
- 2024-03-15 US US18/606,123 patent/US20240360126A1/en active Pending
- 2024-03-18 CL CL2024000791A patent/CL2024000791A1/es unknown
- 2024-03-19 CO CONC2024/0003401A patent/CO2024003401A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240360126A1 (en) | 2024-10-31 |
| CN118076604A (zh) | 2024-05-24 |
| CL2024000791A1 (es) | 2024-09-06 |
| AU2022351495A1 (en) | 2024-02-01 |
| EP4405051A1 (en) | 2024-07-31 |
| IL310443A (en) | 2024-03-01 |
| WO2023046806A1 (en) | 2023-03-30 |
| MX2024003444A (es) | 2024-04-03 |
| PE20250401A1 (es) | 2025-02-11 |
| AR127126A1 (es) | 2023-12-20 |
| CR20240134A (es) | 2024-05-07 |
| JP2024534567A (ja) | 2024-09-20 |
| CO2024003401A2 (es) | 2024-04-29 |
| PE20240815A1 (es) | 2024-04-18 |
| KR20240065092A (ko) | 2024-05-14 |
| TW202328129A (zh) | 2023-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101823488B1 (ko) | 선택적으로 치환된 퀴놀린 화합물 | |
| EP3947367A1 (en) | Protein tyrosine phosphatase inhibitors | |
| EP3802539B1 (en) | Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease | |
| US11952363B2 (en) | Piperazine compounds for the treatment of autoimmune disease | |
| EP3807271A1 (en) | Pyridinyl heterocyclyl compounds for the treatment of autoimmune disease | |
| CA2874445A1 (en) | Tetrahydropyrazolopyrimidine compounds | |
| WO2020064792A1 (en) | Heterocyclyl compounds for the treatment of autoimmune disease | |
| CA3135129A1 (en) | Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease | |
| EP3877388A1 (en) | 5-[6-[[3-(4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl)azetidin-1-yl]methyl]morpholin-4-yl]quinoline-8-carbonitrile derivatives and similar compounds as tlr7-9 antagonists for treating systemic lupus erythematosus | |
| WO2022013136A1 (en) | Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease | |
| CA3228485A1 (en) | Pyrazolo[3,4-b]pyridine compounds for the treatment of autoimmune disease | |
| WO2021105072A1 (en) | 1,8-naphthyridin-2-one compounds for the treatment of autoimmune disease | |
| WO2021099285A1 (en) | Triazatricycle compounds for the treatment of autoimmune disease | |
| EA052162B1 (ru) | СОЕДИНЕНИЯ ПИРАЗОЛО[3,4-b]ПИРИДИНА ДЛЯ ЛЕЧЕНИЯ АУТОИММУННОГО ЗАБОЛЕВАНИЯ | |
| EP4192588A1 (en) | Imidazo[1,2-a]pyridine compounds for the treatment of autoimmune disease | |
| HK40107666A (zh) | 用於治疗自身免疫性疾病的吡唑并[3，4-b]吡啶化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240830 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241218 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241218 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250821 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250821 |